• 1
    International Agency for Research on Cancer. Hepatitis C virus. In: Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 59. Hepatitis viruses. Lyon, France: IARC, 1994: 165221.
  • 2
    Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602610.
  • 3
    Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 2000; 181: 14751478.
  • 4
    Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, et al, for the Hemophilia Growth and Development Study. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001; 26: 466472.
  • 5
    Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107: 10S15S.
  • 6
    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection. JAMA 2000; 284: 450456.
  • 7
    Goedert JJ, Hatzakis A, Maloney EM, Eyster ME, for the Multicenter Hemophilia Cohort Study. Increased liver decompensation risk with atypical hepatitis C virus antibody levels. J Infect Dis 2000; 182: 590594.
  • 8
    Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845851.
  • 9
    Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, de Moerloose P, White GC II, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 15841589.
  • 10
    Goedert JJ, Hatzakis A, Sherman KE, Eyster ME, for the Multicenter Hemophilia Cohort Study. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 2001; 184: 12021205.
  • 11
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562569.
  • 12
    Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240247.
  • 13
    Ragni MV, Mdimbie OK, Rice EO, Bontempo FA, Nedjar S. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV “seroreversion.” Blood 1993; 82: 10101015.
  • 14
    Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9; 11311136.
  • 15
    Briggs NC, Battjes RJ, Cantor KP, Blattner WA, Yellin FM, Wilson S, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users. J Infect Dis 1995; 172: 5158.
  • 16
    Hisada M, Chatterjee N, Zhang M, Battjes RJ, Goedert JJ. Increased hepatitis C virus load among injection drug users infected with human immunodeficiency virus and human T lymphotropic virus type II. J Infect Dis 2003; 188: 891897.
  • 17
    Battjes, RJ, Pickens, RW, Brown, LS. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: An update. J Acquired Immune Defic Syndr 1995; 10: 9096.
  • 18
    Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality associated with HIV and HTLV-II infections among injection drug users in the USA. AIDS 2001; 15: 12951302.
  • 19
    Wiktor SZ, Alexander SS, Shaw GM, Weiss SH, Murphy EL, Wilks RJ, et al. Distinguishing between HTLV-I and HTLV-II by western blot. Lancet 1990; 335: 1533.
  • 20
    Borgan O, Langholz B, Goldstein L, Pogoda J. Lifetime Data Analysis. Exposure stratified case-cohort designs. Lifetime Data Analysis 2000; 6: 3958.
  • 21
    Eforn B, Tibshirani RJ. An introduction for the Bootstrap. In: CoxDR, HinkleyDV, Reid, N, RubinDB, SilvermanBW, eds. Monographs on Statistics and Applied Probability. Vol. 57. London, UK: Chapman and Hall, 1998: 1425.
  • 22
    Efron B. Censored data and the bootstrap. J Amer Stat Assoc 1981; 76: 312319.
  • 23
    Burr D. A comparison of certain confidence intervals in the Cox model. J Amer Stat Assoc 1994; 89: 12901302.
  • 24
    Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 11121115.
  • 25
    Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15: 17071715.
  • 26
    Fanning L, Kenny E, Sheehan M, Cannon B, Whelton M, O'Connell J, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. HEPATOLOGY 1999; 29: 904907.
  • 27
    Lagging LM, Garcia CE, Westin J, Wejstal R, Korkrans G, Dhillon AP, et al. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiology 2002; 40: 42244229.
  • 28
    McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 151622.
  • 29
    Alter MJ, Kruszon-Moran D, Nanan OV, McQuilan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 30
    Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000; 181: 3541.
  • 31
    Longhi MS, Cainelli F, Concia E, Vento S. No increase in liver decompensation risk with atypical hepatitis C virus antibody pattern. J Infect Dis 2001; 183: 1428.
  • 32
    Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC, for the HENCORE group. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 21192124.
  • 33
    Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998; 29: 207213.
  • 34
    Knapp S, Hennig BJ, Frodsham AJ, Shang L, Hellier S, Wright M, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55: 362369.
  • 35
    Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125: 10851093.
  • 36
    Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003; 38: 335342.
  • 37
    Zhang T, Li Y, Lai JP, Douglas SD, Metzger DS, O'Brien CP, et al. Alcohol potentiates hepatitis C virus replicon expression. HEPATOLOGY 2003; 38: 5765.
  • 38
    Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997; 16: 445451.
  • 39
    Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 17081713.